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ABSTRACT
Duchenne muscular dystrophy (DMD) is a rare genetic, progressive 
and devastating skeletal and cardiac muscle disorder due to mutation 
of the dystrophin  gene that affects 1 in 3500 young males. Currently, 
there is no curative management for this pathology. The development of 
inducedpluripotent stem cells (iPSCs) offers a promising cell-based strategy 
for the treatment of muscular dystrophy. Several techniques have been 
established to generate functional myogenic progenitor cells derived from 
iPSCs. In addition, technologies in genetic modification using ZFN, TALENs, or 
CRISPR/Cas9 demonstrate potent methods to restore dystrophin expression. 
However, current evidence shows that either iPSCs or gene editing carry 
a risk of oncogenesis caused by the integration of exogenous DNA into the 
recipient gene. Thus, the safety issue is a major challenge for translating 
this method into human clinical applications. This review briefly discussed 
recent developments and progressions of iPSCs as well as genome engineering 
technologies relevant to regenerative medicine, especially for the treatment 
of DMD.
ABSTRAK
Duchenne muscular dystrophy (DMD) adalah kelainan genetic langka yang 
bersifat progresif dan parah yang menyerang otot rangka dan otot jantung, 
disebabkan oleh mutasi gen distrofin yang mempengaruhi 1 dari 3500 laik-laki 
muda. Hingga saat ini, belum ada tata laksana kuratif untuk penyakit DMD. 
Pengembangan induced-pluripotent stem cells (iPSCs) menawarkan strategi 
berbasis sel yang menjanjikan untuk pengobatan distrofi otot. Beberapa 
teknik telah dikembangkan untuk menghasilkan sel-sel progenitor myogenik 
fungsional yang berasal dari iPSCs. Selain itu, teknologi dalam modifikasi 
genetic menggunakan ZFN, TALENs, atau CRISPR/Cas9 menunjukkan metode 
yang potensial dalam mengembalikan ekspresi distrofin. Namun, bukti saat 
ini menunjukkan bahwa iPSCs atau teknologi pengeditan gen membawa 
risiko keganasan yang disebabkan oleh integrasi DNA eksogen kedalam gen 
inang. Dengan demikian, masalah keamanan adalah tantangan utama dalam 
penerapan metode ini untuk pengobatan pada manusia. Tulisan ini akan 
membahas secara singkat perkembangan dan kemajuan teknologi iPSCs 
terbaru serta teknologi rekayasa genom yang relevan dengan kedokteran 
regeneratif, terutama untuk pengobatan DMD.
INTRODUCTION
Duchenne muscular dystrophy 
(DMD) is a severe, pervasive and the most 
common inherited muscular disorder 
that affects young males. The prevalence 
of this muscle pathology ranged from 
0.9 to 16.8 per 100,000 males, while 
the prevalence at the time of birth was 
1.5 to 28.2 per 100,000 live boys.1 It 
is caused by mutation of the X-linked 
dystrophin gene that is located at locus 
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Xp21.2. The milder forms of skeletal and 
cardiomyocyte abnormalities due to 
dystrophin mutations are named Becker 
muscular dystrophy (BMD) and X-linked 
dilated cardiomyopathy (XLDCM), 
respectively. Dystrophin is a bar-shaped 
and intracellular protein that is located 
on the inner side of sarcolemma. 
Together with transmembrane, 
cytoskeletal protein and extracellular 
components, dystrophin forms the 
dystrophin-glycoprotein complex (DCG). 
The essential role of DCG is to create 
a firm linkage between intracellular 
components and extracellular matrix. 
The absence of dystrophin leads to 
sarcolemma breakdown, calcium 
homeostasis disturbance and progressive 
muscle fiber destruction.2
Although proximal muscle wasting 
starts to appear by the age of 3, diagnosis 
is made mostly when patients are 
approximately 5 years of age because 
their locomotion ability is remarkably 
different from that of other children. 
Patients show a positive Gowers sign 
upon standing up and experience 
difficulty maintaining their normal 
gait. The other signs are calf muscle 
hypertrophy and abnormal laboratory 
findings (elevation of creatine kinase). 
Naturally, DMD progresses to respiratory 
muscle insufficiency and cardiac 
failure. The patients frequently become 
ambulation-dependent around their 
13 years old, and if left untreated, the 
mean age at death is around the early 
twenties.3
Although the molecular pathologies 
of DMD have been well known for 
decades, unfortunately, no effective 
medications are currently available. The 
primary objective of the management is to 
restore muscle function. In general, there 
are 3 main approaches for achieving this 
goal: gene therapy, pharmacotherapy, 
and cell-based therapy. Gene therapy 
emphasizes correction of the defective 
dystrophin gene using exon skipping, 
gene transfer, RNA interference, and 
gene-editing technologies, such as zinc 
finger nucleases (ZFN), transcription 
activator-like effector nucleases 
(TALENs) and the clustered regularly 
interspaced short palindromic repeats 
(CRISPR)/CRISPR-associated systems 9 
(Cas9) system. Pharmacology therapy 
focuses on drug development for treating 
complications and health conditions 
related to DMD. Meanwhile, cell-based 
therapy concerns the replacement of 
damaged tissues by providing new 
healthy cell colonies utilizing satellite 
cells, muscle-derived stem cells, muscle-
derived CD133+ cells, embryonic stem 
cells and induced-pluripotent stem 
cells.4 The anti-inflammatory effect 
of corticosteroids has been proven to 
enhance skeletal and cardiac muscle 
function, slow the occurrence of scoliosis 
and respiratory abnormalities, and 
increase the quality of life in patients 
for more than 2 years.5,6 Prednisone 
and deflazacort are the primary 
corticosteroids used for DMD therapy. 
Griggs et al.7 compared the effectiveness 
of deflazacort, prednisone, and placebo 
in  improving   skeletal   muscle strength. 
They found that deflazacort and 
prednisone had significantly increased 
muscle strength compared to placebo. 
However, several adverse effects related 
to long-term steroid administration 
occur, including Cushingoid appearance, 
skin rash, hirsutism, and increased 
body weight. The latter was more 
prominent in the prednisone group.7 To 
overcome the frequent side effects of 
daily corticosteroid usage, Quattrocelli 
et al.8 performed weekly pulse doses of 
corticosteroids in an animal model with 
similar efficacy and lower side effects.
Recently, only a few novel therapies 
have been conditionally approved for 
DMD patients. The most promising agents 
are readthrough therapy (ataluren) and 
exon skipping (eteplirsen). So-called 
readthrough therapy because this 
agent is able to restore the expression 
of dystrophin protein by inhibiting the 
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termination of protein translation. Oral 
administration of a total dose of 40 mg/
kg bodyweight ataluren daily for 48 
weeks improved the 6-minute walk test 
(6MWT) distance compared to placebo 
in boys with nonsense mutation DMD. It 
also has a good safety profile with only 
mild to moderate adverse events.9,10 
Eteplirsen, an exon skipping agent, 
precisely recognized exon 51 and altered 
the function of splicing enzyme to skip 
exon 51 of the DMD pre-mRNA, resulting 
in restoration of mature mRNA and 
production of shortened yet functional 
dystrophin protein.11 A randomized 
controlled study involving boys aged 7 
to 13 years old with DMD suggested that 
eteplirsen was effective in improving 
dystrophin production as well as 
increasing the 6MWT in ambulation 
patients compared to placebo.12
This review briefly discussed recent 
developments and progressions of 
induced-pluripotent stem cells (iPSCs). 
Moreover, the genome engineering 
technologies relevant to regenerative 
medicine, especially for the treatment of 
DMD was also discussed.
DISCUSSION
Techniques for Inducing Somatic Cells 
into Pluripotent Stem Cells
To be characterized as pluripotent 
lineage,  stem  cells have  to  meet  a 
number of criteria, which are able to 
produce cell types from each of three 
embryonic germ layers: ectoderm, 
mesoderm, and endoderm;  generate 
teratoma or  chimeric offspring; 
maintain   normal  karyotype after  serial 
passaging;  and they must  preserve  their 
population quantity by self-renewal. 
Historically,  stem cells were first 
described more than a half century ago 
from mouse bone marrow cells. Under a 
specific environment, these cells are able 
to differentiate  into numerous types of 
mature cells, named  pluripotent  stem 
cells. In 1981, Evans  and Kaufman for 
the first time succeeded in isolating ES 
cells, which were the inner cell mass 
(ICM) taken from delayed-implantation 
blastocysts in mice. Subsequently, these 
cells developed  teratoma when engrafted 
to the flank region of syngeneic male 
mice.13,14 Later, in 1998, Thomson et al.15 
differentiated human blastocyst cells in 
vitro into all three embryonic cell lineages 
for the first time called embryonic 
stem cells (ESCs). In addition, following 
injection into immunodeficient mice, 
human blastocysts produced teratomas, 
which verified their pluripotency.15
There was a major medical science 
breakthrough in 2006, where scientists 
succeeded in reprogramming mouse 
fibroblasts into pluripotent cells using4 
transcription factors: Oct3/4; Sox2; 
Klf4; and c-Myc, with retrovirus as a 
vector. These cells are termed induced-
pluripotent stem cells (iPSCs).16 In the 
next year, two groups of scientists 
generated human iPSCs from human 
dermal fibroblasts (HDFs) by using 
different transcription cocktails. Human 
iPSCs are indistinguishable from human 
ESCs in morphology, surface antigens, 
protein expression, and telomerase 
activities. This proof of pluripotency 
was strengthened by transplantation of 
human iPSCs to immunodeficient mice, 
resulting in the formation of teratomas 
consisting of three elementary germ 
layers: endoderm, mesoderm, and 
ectoderm.17,18
Narita et al.17 generated iPSCs by 
exposing retroviruses containing human 
Oct3/4, Sox2, Klf4, and c-Myc, which 
were the same reprogramming cocktails 
used in generating mouse iPSCs, into 
HDFs under the conditions of human 
ESC culture.17 Other variations of the 
reprogramming cocktail (Oct4, Sox2, 
Nanog, and Lin28) were adequate to 
generate pluripotent stem cells from 
human fibroblasts taken from foetal as 
well as foreskin of the newborn.19 
Oct3/4 and SOX2 are fundamental 
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transcription factors for either 
maintaining pluripotency or inhibiting 
differentiation. These factors are 
controlled by Nanog, which is a 
homeodomain protein essential for 
preserving ES cell pluripotency. Other 
crucial molecular effectors, Foxd3 and 
Setdb1, required for ES cell survival 
are also controlled by Nanog.20 c-Myc 
is a proto-oncogene found in human 
cancer cells. Deletion of c-Myc in mouse 
embryos resulted in death between 9.5 
and 10.5 gestation days with pathological 
conditions found in the heart, pericardium 
and neural tube.21 In contrast to mouse 
ES cells, the role of c-Myc in human 
ES cells provokes apoptosis as well as 
differentiation. However, by reducing 
the adhesion of cells to the extracellular 
matrix, c-Myc does not contribute to self-
renewal. Therefore, c-Myc functions are 
influenced primarily by the cell lineages 
and niches of stem cells. Kruppel-like 
factor 4 (Klf4) is a zinc finger protein 
containing a sequence of amino acids. 
During the quiescent phase of the 
cell, Klf4 levels are highly detectable; 
in contrast, Klf4 almost disappears 
during the proliferation period.22 
Overexpression of Klf4 in cell culture 
provokes DNA synthesis inhibition and 
cell cycle progression.23 Newbornmice 
from Klf4 null embryos die in 15 hours 
with abnormalities found in the skin 
and colon. This finding suggests the role 
of Klf4 as a tumor suppressor gene.24,25 
On the other hand, overexpressed 
Klf4 is found in both breast cancers 
and squamous cell carcinomas.26,27 It 
also initiates dysplasia of squamous 
epithelial cells in basal keratinocytes.28 
Consequently, Klf4 can act as both a 
tumor suppressor gene and oncogene.29
FIGURE 1. Roles of the four transcription factors in the induction of 
iPSCs. adopted and modified from Yamanaka,28
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The first pioneering iPSC trial used 
retroviral and lentiviral-based methods 
for transfecting somatic cells. However, 
utilization of these vectors is related to 
safety issues because the integration of 
their viral genes increases the likelihood 
of activating endogenous oncogenes 
that can be transformed into malignant 
conditions. Consequently, recent non-
integrating viral vectors have been 
proposed, for example, adenovirus and 
Sendai virus. Adenoviral vectors that 
express c-Myc, Klf4, Oct4, and Sox2 have 
been successfully used to create human 
iPSCs from embryonic fibroblasts. Viral 
DNA was not integrated into iPSCs, as 
proven by Southern blots and polymerase 
chain reaction (PCR) analysis. However, 
the overall efficiency using this technique 
was quite low, ranging from less than 
0.0001 to 0.001% compared with 0.01 
to 0.1% by integrating virus. This is 
presumably due to viral expression 
that cannot be maintained long enough 
to stimulate endogenous pluripotency 
factors.30 Because the efficiency of 
the adenoviral vector was extremely 
low, Sendai virus was introduced for 
transfecting the target cells. Sendai 
virus, a family of Paramyxoviridae, is 
a nonpathogenic, single-stranded RNA 
virus with envelopes that can infect cells 
by replicating only in the cytoplasm. 
Their gene will not be inserted into the 
host genome. Generating iPSCs from 
human fibroblasts and peripheral blood 
mononuclear cells through this vector 
shows an efficiency of 0,1%.31
Apart from viral transfection 
methods, there are various nonviral 
approaches,    including    episomal 
plasmids, modified messenger RNAs 
(mRNAs), microRNAs (miRNAs), small 
molecules and piggyBac transposons. 
Most of those techniques are non-
integrating systems, except for piggyBac 
transposon technology.32
Administration of two different 
plasmids into mouse embryonic 
fibroblasts, the first contains 
complementary DNA of Oct3/4, Sox2, 
and Klf4, while the second plasmid 
contains complementary DNA of 
c-Myc created iPSCs without evidence 
of plasmid integration into host cells. 
Although this method reduces the risk 
of tumorigenicity theoretically, the 
efficiency is remarkably lower than 
that of viral integrating methods.34 
Convenient and nonmutagenic modified 
mRNA exhibited an efficiency of 4.4%, 
which was the highest achievement 
when 5 reprogramming factors, 
including Klf4, Sox2, Oct4, c-Myc, and 
Lin28, were transfected into human 
fibroblasts combined with valproic 
acid (VPA)-supplemented media and 
low oxygen culture conditions.35 
miRNA is an endogen, small non-
coding RNA that has approximately 22 
nucleotides. Because miRNA controls 
gene expression post-transcription, it 
can be involved in embryo maturation, 
stem cell differentiation and apoptosis.36 
TABLE 1. Overview of current reprogramming methods
Systems
Vector
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TABLE 2. Summary of reprogramming methods.
Methods* Advantages Disadvantages
Retrovirus16,17 •	 High efficiency
•	 Simple protocols
•	 Potential to activate an endogenous 
oncogene
•	 Risk of carcinogenesis
Lentivirus18 •	 High efficiency
•	 Simple protocols
•	 Potential to activate an endogenous 
oncogene
•	 Risk of carcinogenesis
Adenovirus30 •	 Non-integrating viral 
genome
•	 Extremely low efficiency





Plasmids34 •	 Non-integrating plasmid 
DNA
•	 Low efficiency
mRNA35 •	 Higher efficiency than 
standard viral approaches
•	 Complex protocols
miRNA36 •	 High efficiency •	 Unstable
•	 Risk of off-target effect
Small molecules37 •	 High efficiency •	 Lack of validated protocols
•	 Limited used in clinical trials
PiggyBac 
transposon33
•	 High efficiency •	 Potential causing epigenetic alter-
ation
*Each method has its own benefit and drawback in terms of safety, efficiency, and proce-
dural complexity
Moreover, miRNA has the capacity to 
reprogram a somatic cell with a high 
level of efficiency. Inducing human 
foreskin and dermal fibroblasts with 
miR302/367 resulted in an efficiency up 
to two orders of magnitude higher than 
that of standard transcription cocktails. 
Approximately 10% of iPSC clones were 
produced by this approach.37
The combination of small molecules 
may address particular signaling 
pathways and mechanisms leading to 
pluripotent stem cell induction. However, 
in vitro reprogramming efficiency is 
affected by the type of somatic cells, the 
condition of culture and the combination 
of compounds used.38 The PiggyBac 
transposon method provides high 
efficiency to reprogram human somatic 
cells into iPSCs. However, microdeletions 
have been shown at the excision sites of 
mouse ESCs that could be an oncogenic 
transformation.33
Generation of Myogenic Progenitor 
Cells from Induced Pluripotent Stem 
Cells
Myogenesis development is initiated 
during the early embryonic period. 
Presomitic mesodermal cells are 
differentiated from pluripotent stem 
cells by expressing myogenin 1, which 
works as a key regulator of unsegmental 
presomitic mesodermal formation. 
Segmental somites are formed afterward. 
Expression of the Pax3 and Pax7 genes 
in the presomitic mesoderm leads to 
myogenic progenitor cell generation. 
Pax3 and pax7 are essential regulatory 
factors for myogenic progenitor cell 
formation. Then, upregulation of MyoD 
and Myf5 in the dorsomedial lip of 
dermomyotome together with Mrf4 
function as a master regulator for 
differentiation of myogenic progenitor 
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cells into myoblasts. Eventually, the 
expression of myogenin triggers the 
formation of a terminal differentiated 
FIGURE 2. Hierarchal master transcription factor cascade for myogenesis. Adopted 
and modified from Kodaka et al.39
activated cell sorting by day 20. However, 
after 3 passages in E6 media, the number 
of iMPCs was extremely decreased. These 
iMPCs exhibited copious expression of 
early myogenic markers, Pax3 (more 
than 70%) and Myf5 (approximately 
80%). In contrast, only a small percentage 
of later myogenic markers MyoD and 
myogenin were shown, approximately 
4% and 2%, respectively. After culturing 
for 4 days in differentiation medium, 
the expression of MyoD and MyoG 
increased with a subsequent decrease 
in GFP. iMPCs formed spindle-shaped 
and obtained elongated nuclei, typical 
morphology of myocytes. Eventually, 
following two weeks of differentiation, 
multinucleated myotubes that contract 
spontaneously were already available. 
Overall, up to 200 million iMPCs were 
obtained by this protocol beginning with 
only 300 thousand iPSCs.40 Both human 
iPSCs and human ESC-derived myogenic 
progenitors substantively demonstrated 
similar expression of surface markers, 
including CD56, CD29, CD44, M-cadherin, 
and alpha 7-integrin. Although murine 
satellite cells and myogenic progenitors 
type of cell, which are multinucleated 
myotubes.39
Both transgene or transgene-free 
methods are applicable for generating 
myogenic progenitor cells from iPSCs. 
Transgene-free or direct reprogramming 
uses myogenic reprogramming, for 
example, Pax3, Pax7 and MyoD. On 
the other hand, the transgene-free 
method involves small compounds or 
cytokines to either impede or stimulate 
the signaling pathway, particularly for 
inducing skeletal muscle formation. 
Despite the ability of a small molecule 
to generate multinucleated myotubes, it 
is inefficient,  comparatively  weak  and 
does not provide a genuine myogenic 
clone. Therefore, its application in 
extensive-scale drug screening and cell-
based therapy trials is undecided. In 
contrast, direct reprogramming protocols 
are quick  and efficient, resulting  in 
more than 90% pure myogenic clones.29
Rao et al.40 transduced iPSCs with 
lentivirus encoding doxycycline that 
expresses Pax7 and green fluorescent 
protein (GFP) in E6 media. More than 
40% pure GFP- and Pax7-expressing cells, 
termed induced myogenic progenitor 
cells (iMPCs), are yielded by fluorescence-
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express these surface markers, thus 
far, only CD56 has been recognized as a 
human satellite cell marker.41
One of the transgene-free protocols 
was established by Choi et al.42 They 
employed two combinations of a small 
compound, CHIR99021 and DAPT. 
The role of CHIR99021 is to activate 
the canonical Wnt signaling pathway. 
Together with the PI3K inhibition 
pathway, activation of the Wnt signal 
is adequate for generating myogenic 
progenitors from iPSCs. Exposure of 
human iPSCs with CHIR99021 in defined 
N2 media for 4 days potentially increased 
the expression of Mesogenin1, a specific 
marker for the pre-somite mesoderm 
line, TBX6, and Pax3. Next, muscle 
progenitor cells that express MyHC, 
MyoG and MyoD appeared after 40 days 
of differentiation. Supplementation of 
the culture between days 4 and 12 with 
DAPT, an inhibitor of gamma-secretase 
that  blocks  Notch  signaling,  increased 
the efficiency and effectiveness of 
myogenic differentiation.  In  addition, 
using exactly the same protocol, they 
could generate human iPSCs derived 
from DMD patients into myoblasts 
without evidence of dystrophin 
gene expression. In contrast, control 
myoblasts derived from healthy humans 
displayed dystrophin protein.42
Gene-editing Technology for 
Correction  of  Genetic  Defect
Approximately  60% of DMD patients 
have mutations in exons 45-55 that 
interrupt  the  translational reading 
frame of  the gene, which  aborts the 
translational process, resulting in 
dystrophin deficiency. Meanwhile, 
mutations with preservation of the 
reading frame create a milder form of 
skeletal muscle abnormality, named 
Becker muscular dystrophy (BMD). 
Hence, deletion of this region by genetic 
mutations provides a therapeutic 
approach for DMD patients affected by 
exon 45-55 mutations.43
Either a small part or entire gene 
could be excised from or transferred 
into a particular chromosome, yielding 
different gene expression. This approach 
is referred to as the gene editing or gene 
correcting technique. In the early 2000s, 
zinc finger nucleases (ZFNs) were widely 
applied for genetic modification. A ZFN 
is a synthetic endonuclease formed by 
designed zinc finger protein (ZFP) and 
restriction  enzyme  FokI. It  works by 
either removing or inserting a specific 
gene,  resulting in gene knockout.44 
Genetic modification of cells from 
DMD patients using ZFN technology 
precisely restored human dystrophin 
gene expression at the sarcolemma 
membrane. However, compared to 
standard nontoxic nuclease (I-SceI), 
this method had a moderate level of 
cytotoxicity.45
Another engineered nuclease, 
transcription activator-like effector 
nucleases (TALENs), is employed 
for editing genome damage at the 
desired site. A designed pair of TALENs 
binds and clamps certain target sites, 
permitting dimerization of FokI and 
breaking the double-stranded DNA.46 
Exposure of TALENs into immortalized 
myoblasts derived from DMD patients 
led to the restoration of dystrophin 
gene expression. In addition, TALENs 
indicated a low grade of cytotoxicity 
similar to I-SceI.47
Alternative to site-specific nucleases, 
clustered regularly interspaced short 
palindromic repeats (CRISPR)/CRISPR-
associated systems 9 (Cas9) have become 
an emerging and popular technology that 
considerably has a facile and efficient 
method.48 (CRISPR/Cas9 was extracted 
from the bacterial adaptive immune 
defense to destroy viral and plasmid 
invasion. The greater efficiency, lower 
toxicity combined with easy targeting 
of specific genome sites compared 
to ZFN and TALENs make CRISPR/
Cas9 a promising method for clinical 
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application.49
A number of trials have been 
conducted by applying CRISPR/Cas9 
myo-editing in animal models. Nelson 
et al. delivered CRISPR/Cas9 using 
adeno-associated virus to excise the 
mutated exon 23 from a DMD mouse 
model. Functional dystrophin protein in 
skeletal and heart muscle was partially 
recovered following the deletion of exon 
23, as shown by improvement of muscle 
strength.50 Amoasii et al.51 injected 
adeno-associated virus (AAV) vectors 
carrying the CRIPSR component either 
intramuscularly or intravenously into 
DMD dog models. After 6 to 8 weeks, they 
found significant improvement in muscle, 
particularly cardiomyocytes.51 Recently, 
a similar method was also performed in 
DMD pigs, resulting in the expression of 
dystrophin in the diaphragm, heart and 
skeletal muscle. Moreover, increasing 
muscle contraction force and twitch 
amplitude enhanced skeletal muscle 
function.52
Young et al.53 performed in vitro 
deletion of exons 45-55 Cas9 from DMD-
derived human iPSCs using a single pair 
of CRIPSR/Cas9. The reframed iPSCs were 
then differentiated into both functional 
skeletal myotubes and cardiomyocytes, 
as demonstrated by improvement of 
cell membrane integrity and recovery of 
the dystrophin glycoprotein complex.53 
Moretti et al.52 generated iPSCs derived 
from DMD patients. Compared to 
iPSCs from healthy young men, DMD-
derived iPSCs expressed notably lower 
concentrations of skeletal muscle 
markers and failed to produce functional 
multinucleated myotubes. Subsequently, 
utilization of AAV-mediated CRISPR/
Cas9 was able to excise exon 51, thus 
stimulating the development of normal 
skeletal and cardiac muscle cells.52 
However, the restoration of functional 
skeletal and cardiac muscle is directly 
proportional to the dosage of AAV-
mediated CRISPR/Cas9 administered. 
Comparison of systemic delivery of 
high-dose (1x1012 vg/mouse) and low-
dose (3x1011  vg/mouse) AAV-CRISPR/Cas9 
in 3-day-old mdx mice showed better 
formation of dystrophin-positive cardiac 
muscle as well as contractility of the 
heart in the high-dose therapy group.54 A 
similar result was also demonstrated in 
a canine model in which a higher dose of 
virus particles significantly ameliorated 
the expression of dystrophin protein 
compared to a lower dose.51
Cell-based Therapy Approach for 
Duchenne Muscular Dystrophy
The significant evolution of human 
iPSCs opens a new era in life science, 
including disease modelling, drug 
discovery and regenerative medicine. 
Compared to traditional cellular 
screening, the human iPSC method 
has enormous advantages, including 
human origin, reproducibility, infinitely 
expandability, plasticity to generate 
almost any cell lines and avoidance of an 
ethical issue related to human ES cells. 
Furthermore, personalized medicine 
that aims to treat medical conditions 
precisely for each individual has the 
potential to be developed by using 
human iPSC technology.55
Animals such as mice have offered a 
meaningful tool for the study of human 
disease, allowing the recognition of 
pathological conditions in a certain type 
of cell for every stage of development. 
However, due to fundamental species 
differences between humans and mice, 
it is impossible to learn the entire 
spectrum of human disease pathology. 
Although patient-derived cells are 
important to learn about human disease, 
they are difficult to access, for example, 
brain cells and heart cells. Thus, human 
iPSCs provide an alternative method 
because they have the competency to 
differentiate into almost every cell type. 
They can also be obtained from easily 
accessible cells such as skin fibroblasts 
and blood cells.56
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Cell-based therapy involves 
engrafting of myogenic progenitor 
or skeletal muscle cells competent 
to produce functional dystrophin-
expressing cells into DMD patients, 
either intramuscularly or systemically. 
Ideally, the cells should be able to reach 
not only skeletal muscle but also the 
heart and diaphragm,  thus, systemic 
administration is preferred over 
intramuscular administration. These 
cells can be obtained from a healthy 
donor without genetic modification 
(allograft) or patients’ own cells 
genetically corrected (autologous). 
Although autograft cells are mutation-
free, they increase the risk of rejection 
from the donor’s immune system.57,58
FIGURE  3. Scheme of the iPSC-based therapy potential for Duchenne muscular 
dystrophy. Adopted and modified from Danisovic et al.29
In 2013, scientists successfully 
transplanted autologous engineered 
iPSCs to mdx dystrophic mice for the 
first time. They used tail-tip fibroblasts 
(TTFs) from  dystrophin/utrophin-
deficient  mice to generate iPSCs using 
reprogramming cocktails (Oct4, Klf4, 
and Sox2) by retroviral transduction. 
The micro-utrophin  (UTRN) gene was 
inserted using the Sleeping Beauty 
transposon to correct dystrophin lack 
iPSCs followed by induction of Pax3, 
which generated myogenic progenitor 
cells (MPCs). These cells were engrafted 
to the tibialis anterior (TA) muscle of 
dystrophic mice, resulting in muscle 
regeneration and improved contractility 
as well as satellite cell compartment 
seeding.59 Kyrychenko et al.58 generated 
DMD model iPSCs by removing exons 
8 and 9 using the CRISPR/Cas9 system. 
To correct these DMD-iPSCs, they 
performed three different methods 
with CRISPR/Cas9 by deleting exons 3-9, 
6-9, or 7-11, resulting in restoration of 
the dystrophin reading frame, which 
subsequently became functional iPSC-
derived cardiomyocytes.58
Another study demonstrated 
amelioration in mdx mice treated with 
myogenic progenitor cells from iPSCs of 
normal mice.  It was  shown by  a decrease 
in both fibrotic tissue and central nuclei, 
which are notable characteristics in 
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muscular dystrophy. Furthermore, they 
also reported improvement of dystrophin 
distribution, acetylcholine receptor 
expression, and Pax7 expression. The 
latter is a fundamental factor for muscle 
progenitor biogenesis.59
Induced-pluripotent stem cells can 
be applied for treating skeletal muscle 
abnormalities as well as cardiomyopathy. 
However, because of its medical, 
technical, and safety issues, until now, no 
human clinical trial using iPSCs has been 
conducted to treat DMD.4 To date, only a 
few clinical trials in terms of cell-based 
therapy for human DMD cases have 
been conducted. Mendell et al.60 failed 
to improve skeletal muscle strength in 
DMD patients after several injections of 
myoblasts into the biceps brachii muscle 
donated from the patient’s father or 
brother. Transplantation of autologous 
muscle-derived CD133 stem cells to 
DMD patients was a safe and feasible 
procedure. Muscle-derived CD133 cells 
display various myogenic markers, 
including Myf5, Mrf4, and MyHCs. Four 
of the five patients showed an increasing 
number of capillaries in each myofiber, 
and two of them showed a conversion 
of slow myosin myofibers into the 
fast type.61 However, to increase the 
therapeutic effectiveness of cell-based 
therapy in DMD, the systemic route for 
distributing engineered cells to diseased 
muscle has to be established.
For the first time, in 2015, Cossu 
et al.62 performed intra-arterial 
transplantation of  HLA-matched 
mesangioblasts  in  5 DMD patients 
under an immunosuppressive regimen 
(tacrolimus). Mesangioblasts were 
obtained from a muscle biopsy of the 
patients’ brothers. Mesangioblasts 
are a subsidiary of pericytes from 
human skeletal muscles. They can 
be expanded and differentiated into 
either skeletal or smooth muscles. 
Interestingly, mesangioblasts have the 
ability to cross the endothelial barrier 
when delivered intra-arterially and 
can also be distributed into muscle 
compartments, as demonstrated in 
animal model experiments. However, 
measurement of muscle function did not 
show notable improvement following 
a series of transplantations. Moreover, 
unfortunately, one of the patients 
experienced a severe adverse event, 
which was an ischemic thalamic stroke.62
Thus, further investigations are 
required to improve the understanding 
of the molecular mechanism controlling 
the characteristics of stem cells in human 
skeletal muscle tissue to achieve feasible, 
reproducible and the most important, 
harmless cell-based therapy in DMD 
patients.
CONCLUSION
The rapid advancement of induced 
pluripotent stem cell technology 
provides the generation of an unlimited 
number of skeletal muscle cells from 
other types of cells, such as fibroblasts 
or white blood cells. This technique is 
a cell-based therapy approach for the 
treatment of various incurable diseases, 
including DMD. Because of mutations 
in a particular gene, the expression of 
dystrophin protein is absent in DMD 
patients, resulting in significant skeletal 
and cardiac muscle dysfunction. Ex 
vivo modification of the genome using 
design endonucleases and CRISPR/Cas9 
has successfully restored the dystrophin 
gene from human iPSC-derived skeletal 
muscle cells. Although animal models 
exhibit improvement of muscle function 
following stem cell transplantation, 
there are several obstacles to applying 
this method in DMD patients. For 
example, gene mutation as a result of 
vector integration could lead to tumor 
formation. The other issues are related 
to immune rejection and adverse effects 
arising from stem transplantation. 
Therefore, further study should be able 
to address these issues  by adopting 
this technology into the human clinical 
territory.
98
J Med Sci, Volume 53, Number 1, 2021 January: 87-102
ACKNOWLEDGEMENT
The authors declare no conflicts of 
interest.
REFFERENCES
1. Crisafulli S, Sultana J, Fontana A, 
Salvo F, Messina S, Trifiro G. Global 
epidemiology of Duchenne muscular 
dystrophy: an updated systematic 
review and meta-analysis. Orphanet 
J Rare Dis 2020; 15(1):141.
https://doi.org/10.1186/s13023-020-01430-8
2. Lapidos KA, Kakkar R, McNally 
EM. The dystrophin glycoprotein 
complex: signaling strength and 
integrity for the sarcolemma. Circ 
Res 2004; 94(8):1023-31.
h t t p s : / / d o i . o r g / 1 0 . 1 1 6 1 / 0 1 .
RES.0000126574.61061.25
3. Bushby K, Finkel R, Birnkrant DJ, 
Case LE, Clemens PR, Cripe L, et 
al. Diagnosis and management of 
Duchenne muscular dystrophy, part 
1: diagnosis, and pharmacological 
and psychosocial management. 
Lancet Neurol 2010; 9(1):77-93.
ht tps : / /do i .org /10 .1016 /S1474-
4422(09)70271-6
4. Łoboda A, Dulak J. Muscle and cardiac 
therapeutic strategies for Duchenne 
muscular dystrophy: past, present, 
and future. Pharmacol Rep 2020;
https://doi.org/10.1007/s43440-020-
00134-x
5. Falzarano MS, Scotton C, Passarelli 
C, Ferlini A. Duchenne muscular 
dystrophy: from diagnosis to therapy. 
Molecules 2015; 20(10):18168-84.
h t t p s : / / d o i . o r g / 1 0 . 3 3 9 0 /
molecules201018168
6. Biggar WD, Harris VA, Eliasoph L, 
Alman B. Long-term benefits of 
deflazacort treatment for boys with 
Duchenne muscular dystrophy in 
their second decade 2006; 16(4):249-55.
https://doi.org/10.1016/j.nmd.2006.01.010
7. Griggs RC, Miller JP, Greenberg CR, 
Fehlings DL, Pestronk A, Mendell JR, 
et al. Efficacy and safety of deflazacort 
vs prednisone and placebo for 
Duchenne muscular dystrophy. 
Neurology 2016; 87(20):2123-31.
h t t p s : / / d o i . o r g / 1 0 . 1 2 1 2 /
WNL.0000000000003217
8. Quattrocelli M, Barefield DY, Warner 
JL, Vo AH, Hadhazy M, Earley JU, et al. 
Intermittent glucocorticoid steroid 
dosing enhances muscle repair 
without eliciting muscle atrophy. J 
Clin Invest 2017; 127(6):2418-32.
https://doi.org/10.1172/JCI91445
9. Bushby K, Finkel R, Wong B, Barohn 
R, Campbell C, Comi GP, et al. Ataluren 
treatment of patients with nonsense 
mutation dystrophinopathy. Muscle 
Nerve 2014; 50(4):477-87.
https://doi.org/10.1002/mus.24332
10. McDonald CM, Campbell C, Torricelli 
RE, Finkel RS, Flanigan KM, Goemans 
N, et al. Ataluren in patients with 
nonsense mutation Duchenne 
muscular dystrophy (ACT DMD): a 
multicentre, randomised, double-
blind, placebo-controlled, phase 3 
trial. Lancet 2017; 390(10101):1489-98.
ht tps : / /do i .org /10 .1016 /S0140-
6736(17)31611-2
11. Lim KRQ, Maruyama R, Yokota 
T. Eteplirsen in the treatment of 
Duchenne muscular dystrophy. Drug 
Des Devel Ther 2017; 11:533-45.
12. Mendell JR, Rodino-Klapac LR, 
Sahenk Z, Roush K, Bird L, Lowes LP, 
et al. Eteplirsen for the treatment of 
Duchenne muscular dystrophy. Ann 
Neurol 2013; 74(5):637-47.
https://doi.org/10.1002/ana.23982
13. Robinton DA, Daley GQ. The promise 
of induced pluripotent stem cells in 
research and therapy. Nature 2012; 
481(7831):295-305.
https://doi.org/10.1038/nature10761
14. Evans MJ, Kaufman MH. Establishment 
in culture of pluripotential cells 
from mouse embryos. Nature 1981; 
292(5819):154-6.
https://doi.org/10.1038/292154a0
15. Thomson JA, Eldor JI, Shapiro SS, 
99
Batubara IS., Induced pluripotent stem cells...
Waknitz MA, Swiergiel JJ, Marshall 
VS, et al. Embryonic stem cell lines 
derived from human blastocysts. 
Science 1998; 282(5391):1145-7.
h t t p s : / / d o i . o r g / 1 0 . 1 1 2 6 /
science.282.5391.1145
16. Takahashi K, Yamanaka S. Induction 
of pluripotent stem cells from mouse 
embryonic and adult fibroblast 
cultures by defined factors. Cell 2006; 
126(4):663-76.
https://doi.org/10.1016/j.cell.2006.07.024
17. Takahashi K,Tanabe K, Ohnuki 
M,Narita M, Ichisaka T, Tomoda K, 
et al. Induction of pluripotent stem 
cells from adult human fibroblasts by 
defined factors. Cell 2007; 131(5):861-72.
https://doi.org/10.1016/j.cell.2007.11.019
18. Yu J, Vodyanik MA, Otto KM, Bourget 
JA, Frane JL, Tian S, et al. Induced 
pluripotent stem cell lines derived 
from human somatic cells. Science 
2007; 318(5858):1917-20.
https://doi.org/10.1126/science.1151526
19. Loh YH, Wu Q, Chew JL, Vega VB, 
Zhang W, Chen X, et al. The Oct4 
and Nanog transcription network 
regulates pluripotency in mouse 
embryonic  stem cells. Nat Genet 
2006; 38(4):431-40.
https://doi.org/10.1038/ng1760
20. Davis AC, Wims M, Spotts GD, Hann 
SR, Bradley A. A null c-myc mutation 
causes lethality before 10.5 days 
of gestation in homozygotes  and 
reduced fertility in heterozygous 
female mice. Genes Dev 1993; 
7(4):671-82.
https:/doi.org/10.1101/gad.7.4.671
21. Sumi T, Tsuneyoshi N, Nakatsuji 
N, Suemori H. Apoptosis and 
differentiation of human embryonic 
stem cells induced by sustained 
activation of c-Myc. Oncogene 2007; 
26(38):5564-76.
https://doi.org/10.1038/sj.onc.1210353
22. Shields JM, Christy RJ, Yang VW. 
Identification and characterization 
of a gene encoding a gut-enriched 
Krüppel-like factor expressed during 
growth arrest. J Biol Chem 1996; 
271(33):20009-17.
https://doi.org/10.1074/jbc.271.33.20009
23. Segre JA, Bauer C, Fuchs E. Klf4 is 
a transcription factor required for 
establishing the barrier function of 
the skin. Nat Genet 1999; 22(4):356-60.
https://doi.org/10.1038/11926
24. Katz JP, Perreault N, Goldstein BG, 
Actman L, McNally SR, Silberg DG, et 
al. Loss of Klf4 in mice causes altered 
proliferation and differentiation and 
precancerous changes in the adult 
stomach. Gastroenterology 2005; 
128(4):935-45.
h t t p s : / / d o i . o r g / 1 0 . 1 0 5 3 / j .
gastro.2005.02.022
25. Foster KW, Ren S, Louro ID, Lobo-
Ruppert SM, McKie-Bell P, Grizzle W, 
et al. Oncogene expression cloning by 
retroviral transduction of adenovirus 
E1A-immortalized rat kidney RK3E 
cells: transformation of a host with 
epithelial features by c-MYC and the 
zinc finger protein GKLF. Cell Growth 
Differ 1999; 10(6):423-34.
26. Foster KW, Frost AR, McKie-Bell P, 
Lin CY, Engler JA, Grizzle WE, et al. 
Increase of GKLF messenger RNA 
and protein expression during 
progression of breast  cancer. Cancer 
Res 2000; 60(22):6488-95.
27. Foster KW,   Liu Z, Nail CD, Li 
X, Fitzgerald  TJ,   Bailey  SK, 
et al.  Induction of KLF4 in 
basal keratinocytes  blocks  the 
proliferation-differentiation switch 
and initiates squamous epithelial 
dysplasia. Oncogene 2005; 24(9):1491-
500.
https://doi.org/10.1038/sj.onc.1208307
28. Yamanaka S. Strategies and new 
developments in the generation of 
patient-specific pluripotent stem 
cells. Cell Stem Cell 2007; 1(1):39-49.
https://doi.org/10.1016/j.stem.2007.05.012
29. Danisovic L, Culenova M, 
Csobonyeiova M. Induced pluripotent 
stem cells for Duchenne muscular 
dystrophy modeling and therapy. 
100
J Med Sci, Volume 53, Number 1, 2021 January: 87-102
Cells 2018; 7(12):253.
https://doi.org/10.3390/cells7120253
30. Zhou W, Freed CR. Adenoviral gene 
delivery can reprogram human 
fibroblasts to induced pluripotent 
stem cells. Stem Cells 2009; 
27(11):2667-74.
https://doi.org/10.1002/stem.201
31. Fusaki N, Hasegawa M, Inoue M, 
Saeki K, Ban H, Shikamura M, et al. 
Efficient generation of transgene-
free human induced pluripotent stem 
cells (iPSCs) by temperature-sensitive 
Sendai virus vectors. Proc Natl Acad 
Sci 2011; 108(34):14234-9.
https://doi.org/10.1073/pnas.1103509108
32. Behringer R, Gertsenstein M, 
Nagy KV, Nagy A. Reprogramming 
mouse fibroblasts with piggyBac 
transposons. Cold Spring Harb Protoc 
2017; 2017(10):827-30.
https://doi.org/10.1101/pdb.prot092627
33. Yusa K, Rad R, Takeda J, Bradley A. 
Generation of transgene-free induced 
pluripotent mouse stem cells by the 
piggyBac transposon. Nat Methods 
2009; 6(5):363-9.
https://doi.org/10.1038/nmeth.1323
34. Okita K, Nakagawa M, Hyenjong H, 
Ichisaka T, Yamanaka S. Generation 
of mouse induced pluripotent stem 
cells without viral vectors. Science 
2008; 322(5903):949-53.
https://doi.org/10.1126/science.1164270
35. Warren L, Manos PD, Ahfeldt T, Loh 
YH, Li H, Lau F, et al. Highly efficient 
reprogramming to pluripotency and 
directed differentiation of human 
cells with synthetic modified mRNA. 
Cell Stem Cell 2010; 7(5):618-30.
https://doi.org/10.1016/j.stem.2010.08.012
36. Anokye-Danso F, Trivedi CM, Juhr 
D, Gupta M, Cui Z, Tian Y, et al. 
Highly efficient miRNA-mediated 
reprogramming of mouse and human 
somatic cells to  pluripotency. Cell 
Stem Cell 2011; 8:376–88.
https://doi.org/10.1016/j.stem.2011.03.001
37. Baranek M, Markiewicz WT, 
Barciszewski J. Selected small 
molecules as inducers of pluripotency. 
Acta Biochim Pol 2016; 63:709–16.
https://doi.org/10.18388/abp.2016_1363
38. Zeng ZL, Lin X long, Tan LL, Liu 
YM, Qu K, Wang Z. MicroRNAs: 
Important Regulators of Induced 
Pluripotent Stem Cell Generation and 




39. Kodaka Y, Rabu G, Asakura A. 
Skeletal muscle cell induction from 
pluripotent stem cells. Stem Cells Int 
2017;2017:1376151.
https://doi.org/10.1155/2017/1376151
40. Rao L, Qian Y, Khodabukus A, 
Ribar T, Bursac N. Engineering 
human pluripotent stem cells into a 




41. Darabi R, Arpke RW, Irion S, Dimos 
JT, Grskovic M, Kyba M, et al. Human 
ES- and iPS-derived myogenic 
progenitors restore DYSTROPHIN 
and improve contractility upon 
transplantation in dystrophic mice. 
Cell Stem Cell 2012; 10(5):610-9.
https://doi.org/10.1016/j.stem.2012.02.015
42. Choi IY, Lim H, Estrellas K, Mula J, 
Cohen TV, Zhang Y, et al. Concordant 
but varied phenotypes among 
Duchenne muscular dystrophy 
patient-specific myoblasts derived 
using a human iPSC-based model. 
Cell Rep 2016; 15(10):2301-12.
h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 / j .
celrep.2016.05.016
43. Zhang Y, Long C, Duby RB, Olson EN. 
Myoediting: toward prevention of 
muscular dystrophy by therapeutic 
genome editing. Physiol Rev 2018; 
98(3):1205-40.
h t t p s : / / d o i . o r g / 1 0 . 1 1 5 2 /
physrev.00046.2017
44. Urnov FD, Rebar EJ, Holmes MC, Zhang 
HS, Gregory PD. Genome editing with 
engineered zinc finger nucleases. Nat 
101
Batubara IS., Induced pluripotent stem cells...
Rev Genet 2010; 11(9):636-46.
https://doi.org/10.1038/nrg2842
45. Ousterout DG, Kabadi AM, Thakore 
PI, Pinera PP, Brown MT, Majoros 
WH, et al. Correction of dystrophin 
expression in cells from Duchenne 
muscular dystrophy patients through 
genomic excision of exon 51 by zinc 
finger nucleases. Mol Ther 2015; 
23(3):523-32.
https://doi.org/10.1038/mt.2014.234
46. Ding Q, Lee YK, Schaefer EAK, 
Peters DT, Veres A, Kim K, et al. A 
TALEN genome-editing system for 
generating human stem cell-based 
disease models. Cell Stem Cell 2013; 
12(2):238-51.
https://doi.org/10.1016/j.stem.2012.11.011
47. Ousterout DG, Pinera PP, Thakore PI, 
Kabadi AM, Brown MT, Qin X, et al. 
Reading frame correction by targeted 
genome editing restores dystrophin 
expression in cells from Duchenne 
muscular dystrophy patients. Mol 
Ther 2013; 21(9):1718-26.
https://doi,org/10.1038/mt.2013.111
48. Gaj T, Gersbach CA, Barbas CF. 
ZFN, TALEN, and CRISPR/Cas-based 
methods for genome engineering. 
Trends Biotechnol 2013; 31:397-405. 
h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j .
tibtech.2013.04.004
49. Mali P, Yang L, Esvelt KM, Aach J, 
Guell M, DiCarlo JE, et al. RNA-guided 
human genome engineering via Cas9. 
Science 2013; 339(6121):823-6.
https://doi.org/10.1126/science.1232033
50. Kishi N, Okano H. Neuroscience 
research using non-human primate 
models and genome editing. In: 
Jaenisch R, Zhang F, Gage F, editors. 
Genome Editing in Neurosciences. 
Research and Perspectives in 
Neurosciences. Springer, Cham (CH); 
2017.
51. Amoasii L, Hildyard JCW, Li H, Ortiz 
ES, Mireault A, Caballero D, et al. 
Gene editing restores dystrophin 
expression in a canine model of 
Duchenne muscular dystrophy. 
Science 2018; 362(6410):86-91.
https://doi.org/10.1126/science.aau1549
52. Moretti A, Fonteyne L, Giesert F, 
Hoppmann P, Meier AB, Bozoglu T, et 
al. Somatic gene editing ameliorates 
skeletal and cardiac muscle failure in 
pig and human models of Duchenne 
muscular dystrophy. Nat Med 2020; 
26(2):207-14.
https://doi.org/10.1038/s41591-019-0738-2
53. Young CS, Hicks MR, Ermolova NV, 
Nakano H, Jan M, Younesi S, et al. A 
Single CRISPR-Cas9 deletion strategy 
that targets the majority of DMD 
patients restores dystrophin function 
in hiPSC-derived muscle cells. Cell 
Stem Cell 2016; 18(4):533-40.
https://doi.org/10.1016/j.stem.2016.01.021
54. Refaey ME, Xu L, Gao Y, Canan BD, 
Adesanya TMA, Warner SC, et al. 
In vivo genome editing restores 
dystrophin expression and cardiac 
function in dystrophic mice. Circ Res 
2017; 121(8):923-9.
h t t p s : / / d o i . o r g / 1 0 . 1 1 6 1 /
CIRCRESAHA.117.310996
55. Shi Y, Inoue H, Wu JC, Yamanaka 
S. Induced pluripotent stem cell 
technology: a decade of progress. Nat 
Rev Drug Discov 2017; 16(2):115-30.
https://doi.org/10.1038/nrd.2016.245
56. Motohashi YS, Komaki H, Motohashi 
N, Takeda S, Yokota T, Aoki Y. Restoring 
dystrophin expression in duchenne 
muscular dystrophy: Current status 
of therapeutic approaches. J Pers 
Med 2019; 9(1):1.
https://doi.org/10.3390/jpm9010001
57. Filareto A, Parker S, Darabi R, Borges 
L, Iacovino M, Schaaf T, et al. An ex 
vivo gene therapy approach to treat 
muscular dystrophy using inducible 
pluripotent stem cells. Nat Commun 
2013; 4:1549.
https://doi.org/10.1038/ncomms2550
58. Kyrychenko V, Kyrychenko S, Tiburcy 
M, Shelton JM, Long C, Schneider 
JW, et al. Functional correction of 
dystrophin actin binding domain 
mutations by genome editing. JCI 
102
J Med Sci, Volume 53, Number 1, 2021 January: 87-102
Insight 2017; 2(18):95918.
https://doi.org/10.1172/jci.insight.95918
59. Cai WF, Huang W, Wang L, Wang JP, 
Zhang L, Ashraf M, et al. Induced 
pluripotent stem cells derived 
muscle progenitors effectively 
mitigate muscular dystrophy 
through restoring the dystrophin 
distribution. J Stem Cell Res Ther 
2016; 6(10):1000361.
h t t p s : / / d o i . o r g / 1 0 . 4 1 7 2 / 2 1 5 7 -
7633.1000361
60. Mendell JR, Kissel JT, Amato AA, 
King W, Signore L, Prior TW, et al. 
Myoblast transfer in the treatment 
of Duchenne’s muscular dystrophy. N 
Engl J Med 1995; 333(13):832-8.
h t t p s : / / d o i . o r g / 1 0 . 1 0 5 6 /
NEJM199509283331303
61. Torrente Y, Belicchi M, Marchesi C, G 
D’Antona, F Cogiamanian, F Pisati,et 
al. Autologous transplantation of 
muscle-derived CD133+ stem cells 
in Duchenne muscle patients. Cell 
Transplant 2014; 16(6):563-77.
h t t p s : / / d o i .
org/10.3727/000000007783465064
62. Cossu G, Previtali SC, Napolitano S, 
Cicalese MP, Tedesco FS, Nicastro F, 
et al. Intra‐arterial transplantation of 
HLA‐matched donor mesoangioblasts 
in Duchenne muscular dystrophy. 
EMBO Mol Med2016; 8(12):1470-1.
h t t p s : / / d o i . o r g / 1 0 . 1 5 2 5 2 /
emmm.201607129
